Sympathetic Cardioneuropathy in Dysautonomias
NEJM 336:696-702, 7211997., Goldstein,D.S.,et al, 1997
Important Advances in Clinical Medicine
West J Med 123:128, Mosier,J.M.,et al, 1975
Parkinsons Disease
NEJM 391:442-452, Tanner,C.M. & Ostrem,J.L., 2024
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Progressive Supranuclear Palsy: A Current Review
The Neurologist 14:79-88, Lubarsky,M. &Juncos,J.L., 2008
Drug Therapy of Parkinsonism
NEJM 295:814, Bianchine,J.R., 1976
Diagnosis and Treatment of Parkinson Disease
JAMA 323:548-560, Armstrong, M.J. & Okun, M.S., 2020
Vitamin B6 Deficiency Presenting with New-Onset Epilepsy and Status Epilepticus in a Patient with Parkinson Disease
Neurol 94:e2605-e2607, Modica, J.S.,et al, 2020
Dopa-Responsive Dystonia Revisited
Arch Neurol 69:1558-1562, Tadic, V.,et al, 2012
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Levodopa for the Treatment of Parkinsons Disease
NEJM 359:2468-2476, LeWitt,P.A., 2008
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Clinicopath Conf, Dopamine-Responsive-Dystonia Caused by a Mutation in the GCH1 Gene
NEJM 355:831-839, Case 26-2006, 2006
Diagnosis and Initial Management of Parkinsons Disease
NEJM 353:1021-1027, Nutt,J.G.&Wooten,G.F., 2005
Stalevo for Parkinson's Disease
The Medical Letter 46:39, , 2004
Levodopa and the Progression of Parkinson's Disease
NEJM 351:2498-2508, The Parkinson Study Group, 2004
Treatments of Parkinson Disease
Arch Neurol 60:1680-1684, Shults,C.W., 2003
Practice Parameter: Initiation of Treatment for Parkinson's Disease: An Evidence-based Review
Neurol 58:11-17, Miyasaki,J.M.,et al, 2002
Ten-year Follow-up of Three Different Initial Treatments in De-novo PD
Neurol 57:1687-1694, Lees,A.J.,et al, 2001
Spinocerebellar Ataxia Type 2 Presenting as Familial Levodopa-Responsive Parkinsonism
Ann Neurol 50:812-815, Shan,D.,et al, 2001
Quetiapine for L-Dopa-Induced Psychosis in PD
Neurol 54:1538, Weiner,W.J.,et al, 2000
The Catechol-O-Methyltransferase (COMT) Inhibitor Entacapone Enhances the Pharmacokinetic and Clinical Response to Sinemet CR in Parkinson's Disease
JNNP 68:589-594, Piccinni,P.,et al, 2000
Immediate-Release and Controlled-Release Carbidopa/Levodopa in PD, A 5-Year Randomized Multicenter Study
Neurol 53:1012-1019, Koller,W.C.,et al, 1999
Investig of PDRG of UK into Excess Mortality Seen/Comb Levodopa & Selegiline Trmt in Pts with Early, Mild Parkinson's Dis
BMJ 316:1191-1196, Ben-Shlomo,Y.,et al, 1998
Random, Placebo-Contr Study of Tolcapone in Pts with Fluctuating Parkinson Dis Trtd With Levodopa-Carbidopa
Arch Neurol 55:1089-1095, Adler,C.H.,et al, 1998
Cabergoline Treatment of Early Parkinson's Disease:First Yr of Trtm Comparison of Cabergoline & Levodopa
Neurol 48:363-368, Rinne,U.K.,et al, 1997
Comparative Study of Selegiline Plus L-Dopa-Carbidopa VS L-Dopa-Carbidopa Alone in Trtm of Parkinson's Disease
Ann Neurol 37:95-98, Brannan,T.&Yahr,M.D., 1995
Neuroleptic Drug Exposure and Treatment of Parkinsonism in the Elderly:A Case-Control Study
Am J Med 99:48-54, Avorn,J.,et al, 1995
Increased Incidence of Levodopa Therapy Following Metoclopramide Use
JAMA 274:1780-1782, Avorn,J.,et al, 1995
Comparison of Therapeutic Effects & Mortality Data of Levodopa & Levodopa with Selegiline in Pts with Early, Mild Parkinson's
BMJ 311:1602-1607, 15831995., Lee,A.J.,et al, 1995
The Effect of Deprenyl and Levodopa on the Progression of Parkinson's Disease
Ann Neurol 38:771-777, Olanow,C.W.,et al, 1995
A Multicenter Double-Blind Placebo-Controlled Trial of Pergolide as an Adjunct to Sinemet in Parkinson's Disease
Movement Disorders, 9:40-471994., Olanow,C.W.,et al, 1994
Clinical Experience with Controlled-Release Carbidopa/Levodopa in Parkinson's Disease
Neurol 43:677-681, Pahwa,R.,et al, 1993
Levodopa Improves Spatial Contrast Sensitivity in Parkinson's Disease
Arch Neurol 50:721-724, Hutton,J.T.,et al, 1993
Levodopa-Nonresponsive Lewy Body Parkinsonism:Clinicopathologic Study of Two Cases
Neurol 42:1323-1327, Mark,M.H.,et al, 1992
The Effect of Exercise on Levodopa Absorption
Neurol 42:2042-2045, Carter,J.H.,et al, 1992
Apomorphine Test for Dopaminergic Response in Pts with Previously Untreated Parkinson's
Arch Neurol 49:1131-1134, Gasser,T.,et al, 1992
Early Combination of Selegiline and Low-Dose Levodopa as Initial Symptomatic Therapy in Parkinson's Dis
Arch Neurol 48:31-34, Elizan,T.S.,et al, 1991
Standard & Controlled-Release Levodopa/Carbidopa in Fluctuating Parkinson's Disease on a Protein Redistribution Diet
Arch Neurol 48:402-405, Karstaedt,P.J.,et al, 1991
Neuroleptic Malignant Synd in Parkinson's after Withdrawal or Alteration of Dopaminergic Therapy
Arch Int Med 151:794-796, Keyser,D.L.&Rodnitzky,R.L., 1991
A Comparison of Effects of Controlled-Release Levodopa (Madopar CR) with Levodopa in Late Parkinson's Disease
JNNP 53:220-223, MacMahon,D.G.,et al, 1990
A Double-Blind Crossover Comparison of Sinemet CR4 and Standard Sinemet 25/100 in Patients with Parkinson's Disease
JNNP 52:207-212, Cedarbaum,J.M.,et al, 1989
Dose-Dependent Memory Impairment in Parkinson's Disease
Neurol 39:438-440, Huber,S.J.,et al, 1989
Dopa Responsive Dystonia:A Treatable Condition Misdiagnosed as Cerebral Palsy
BMJ 298:1019-1020, Boyd,K.&Patterson,V., 1989
Controlled-Release Carbidopa/Levodopa (CR4-Sinemet) in Parkinson's Disease Pts With & Without Motor Fluctuations
Neurol 38:1143-1146, Goetz,C.G.,et al, 1988
Treatment of Chronic Parkinson's Disease with Controlled-Release Carbidopa/Levodopa
Arch Neurol 45:861-864, Hutton,J.T.,et al, 1988
Early Combination of Bromocriptine & Levodopa in the Treatment of Parkinson's Disease:A 5-Year Follow-up
Neurol 37:826-828, Rinne,U.K., 1987
Parkinson's Disease & Motor Fluctuations:Long-Acting Carbidopa. Levodopa (CR-4-Sinemet)
Neurol 37:875-878, Goetz,C.G.,et al, 1987
Dietary Influence on the Antiparkinsonian Response to Levodopa
Arch Neurol 44:1003-1005, Juncos,J.L.,et al, 1987